AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. secured $37 million in Series A financing led by InnoPinnacle Fund to advance AHB-137 clinical development for HBV cure.
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. secured $37 million in Series A financing led by InnoPinnacle Fund to advance AHB-137 clinical development for HBV cure.
07/15/24, 1:29 AM
Location
san mateoMoney raised
$37 million
Industry
biopharma
therapeutics
biotechnology
health care
Round Type
series a
Investors
Genesis Capital, Hankang Capital, Qiming Venture Partners, Yuanbio Venture Capital, Inno Pinnacle Fund
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. announced the completion of a $37 million Series A financing round to further support the clinical development of AHB-137, their lead product candidate, and advance their proprietary Med-Oligo™ technology platform and product pipelines.
Company Info
Location
san mateo, california, united states
Additional Info
AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-OligoTM ASO platform with novel insights into ASO design and capabilities to substantially enhance the current ASO therapeutics. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligosTM Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases.